5 REASONS WHY RAFAEL HOLDINGS IS A RISKY INVESTMEN
Post# of 24
$RFL
Rafael Holdings Inc, whose subsidiaries include Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd, has announced a realignment of the management team.
The move comes on the heels of the Company’s subsidiary Rafael Pharmaceuticals announcing that its lead candidate devimistat (CPI-613) failed to achieve its primary objective of overall survival (OS) in a crucial Phase III trial and another trial in acute myeloid leukemia (AML) was halted due to lack of efficacy.
We take a look at the Company's pipeline and its prospects in our article today.
Read on to know more:
https://www.aviseanalytics.com/5-reasons-why-...nvestment/